Tvardi Therapeutics (FRA:69C) Insider Ownership: 0.00 % (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:69C Tvardi Therapeutics Inc FRA:69C
19 GF Score
Price €1.42
! 1 Warning Sign
View Full Analysis

What is Tvardi Therapeutics Insider Ownership?

Tvardi Therapeutics FRA:69C -8.39% 19 Insider Ownership is 0.00 % as of Sep. 16, 2026. GuruFocus rates FRA:69C with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Tvardi Therapeutics's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Tvardi Therapeutics's Institutional Ownership is 5.65%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Tvardi Therapeutics's Float Percentage Of Total Shares Outstanding is 99.61%.

Tvardi Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Insider Ownership Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Insider Ownership
0.00 0.00 0.00 0.00

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:69C
19GF Score
Tvardi Therapeutics Inc FRA:69C
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tvardi Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Tvardi Therapeutics (FRA:69C) has a Insider Ownership of 0.00 % as of Sep. 16, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Tvardi Therapeutics and its competitors.
Is Tvardi Therapeutics' Insider Ownership too high?
Tvardi Therapeutics' current Insider Ownership is 0.00 %. Overall, Tvardi Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Insider Ownership compare to PVCT and CLRB?
Tvardi Therapeutics' Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (FRA:69C) has a current Insider Ownership of 0.00 %. The current Insider Ownership is 0.00 %. Tvardi Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Tvardi Therapeutics (FRA:69C), the current Insider Ownership is 0.00 % as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
19GF Score

Get the complete analysis for FRA:69C

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.42
Price